Life sciences briefing: Friday, Feb. 22, 2008
TODAY’S HEADLINES:
HemCon Medical acquires Alltracel Pharma (release)
Transoma Medical, implantable wireless device maker, withdraws its IPO (Edgar)
Oracle Healthcare cuts Precision Thera acquisition price by roughly 15 percent (release)
MedBillManager adopts change:healthcare name, aims for March 3 relaunch release
Another slow news day, as yesterday we covered most of the fundings other sites are writing about today. I’ll update if anything else crops up. In the meantime, feel free to check out yesterday’s briefing or any other items here.
HemCon… Continue Reading
IPO status board: The good, the bad and the pending
Now that the Bioheart IPO has doubly surprised everyone — first by happening at all, and second by coming out on such dreadful terms for the company — perhaps it’s time to take a closer look at exactly where the 2008 offering market for life-science companies stands. In fact, I’ll aim to make this a regular feature, because the IPO market is still a useful leading indicator for venture funding.
Data for the following analysis comes… Continue Reading
Life sciences briefing: Monday, Feb. 18, 2008
TODAY’S HEADLINES:
Sweden’s Elekta buys radiation-therapy software maker CMS for $75M (release)
Infusion-services firm Critical Homecare withdraws $125M IPO for buyout (Edgar)
NOTE: It’s a slow news day thanks to the President’s Day holiday. I’ll update with whatever else comes over the transom later today.
Sweden’s Elekta buys radiation-therapy software maker CMS for $75M – CMS, a St. Louis, Mo., developer of software for planning and managing radiation-therapy treatments, sold itself to Sweden’s Elekta for roughly $75 million in cash. The… Continue Reading
Life sciences briefing: Friday, Feb. 15, 2008
TODAY’S HEADLINES:
Q Thera takes in $15M for neural stem-cell treatments (release)
Stroke clotbuster Concentric Medical withdraws IPO (IPOhome)
Avera recaps with $9M to relaunch human tests of GI drug (VentureWire)
Tissue repairer Nerites raises $5.7M (release)
Semafore Pharma aims for $7.5M to launch new cancer-drug trials (VentureWire)
Triage Wireless gets $6.7M for “cuffless” blood-pressure monitors (peHUB)
MAKO Surgicals prices IPO, falls in first day of trading (WSJ)
ImmunoCellular acquires assets of Molecular Antibody Technology (release)
Q Thera takes in $15M for neural stem-cell… Continue Reading
Levitation option still valid for Wile E. Coyote
Fresh from the Department of Whistling Past the Graveyard in today’s VentureWire:
Back in the real world, seven life-science IPOs have gone down in flames so far this year. An eighth startup, robotic-surgery maker MAKO Surgical, just slashed its offering price.
Life sciences briefing: Monday, Feb. 11, 2008
TODAY’S HEADLINES:
PolyRemedy, developer of robotic wound care, takes in $25M (release)
Bacchus Vascular gets $15M for clot-busting device (VentureWire)
Protein-evolution company Modular Genetics gets $1.2M (VentureWire)
PharmatrophiX gets $300K for Alzheimer’s disease prevention drugs (release)
Light Sciences Oncology withdraws IPO (Edgar)
Arizona’s Translational Accelerator launches $20M life-sciences fund (bizjournals.com)
Cornea-reshaper Avedro gets $7M (VentureWire)
Gastrotech Pharma gets $6M in wake of Lilly deal (VentureWire)
Biomaterials maker MiMedx goes public via reverse merger (release)
Acrongenomics to complete acquisition of Molecular Vision by the end of… Continue Reading
Life-science IPOs hit the skids
Last year was a tough one for IPOs, as Matt noted earlier, and so far this year looks even worse. Aptamer-drug maker Archemix today became the third life-science startup this month to withdraw or postpone an IPO, and the sixth so far this year. We take a closer look at the worsening IPO climate and the contrast with still-bullish venture funding in the sector, over at VentureBeat Life Sciences.
IPO roundup: Is the window slamming on life sciences?
It’s sure starting to look that way. News that Archemix, a Cambridge, Mass., developer of aptamer-based drugs, yesterday withdrew its $72.5 million IPO follows closely on the heels of several other recent several other IPO collapses, including those of implantable diagnostic maker Transoma Medical and biotechs Biolex Therapeutics and BG Medicine. (Our coverage is here, here and here.) Transoma, in fact, had set its offering terms just a few weeks earlier. Most everyone, of course,… Continue Reading
Life sciences briefing: Wednesday, Jan. 23, 2008
TODAY’S HEADLINES:
Mauna Kea Tech raises $30M for in-vivo cellular imaging (release)
Knopp Neuro takes in $10M for Lou Gehrig’s drug (release)
Cardiovascular Systems, arterial-plaque device maker, files for $86M IPO (Edgar)
Diagnostics maker BG Medicine withdraws IPO (release)
Signature Genomics Labs sells stake to Ampersand Ventures (release)
Cambridge Temp raises £375K for new ovulation detector (release)
Mauna Kea Tech raises $30M for in-vivo cellular imaging — Mauna Kea Technologies, a Paris, France, developer of cellular-imaging technology, raised $30 million in a… Continue Reading
Life sciences briefing: Monday, Oct. 8, 2007
Featured companies: AirInSpace, Anacor Pharmaceuticals, Apollo Endosurgery, Ascension Health Partners, BG Medicine, CeraPedics, GlaxoSmithKline, Simplex Diabetic Supply, Zars Pharma
UPDATED: Last entry added at 2am PT on 10/8/07.
Anacor Pharma pulls in $22M from Glaxo, with hundreds of millions more on the line –Palo Alto, Calif.-based Anacor Pharmaceuticals, a biotech developing new anti-infective and anti-inflammatory drugs using boron chemistry, struck a wide-ranging partnership with GlaxoSmithKline worth up to $605 million. Anacor will receive a $12 million cash payment and… Continue Reading